Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market

US FDA approval of Sublocade, the company's once-monthly buprenorphine depot injection, may help Indivior defend its opioid addiction franchise from generics and the competing Alkermes product Vivitrol. But another new rival is expected soon – a once-monthly product from Braeburn.

ApproveOnKeyboard_1200x675

FDA approval of Indivior PLC's Sublocade (buprenorphine extended-release) gives healthcare professionals another weapon to fight the growing opioid addiction epidemic in the US. It also gives the UK-based company another product in the battle to maintain its dominant share of the opioid use disorder (OUD) market.

Indivior has seen the market share for its blockbuster OUD treatment Suboxone (buprenorphine/naloxone) sublingual film dip slightly as price-sensitive payers...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip